Calendario›CORT›Mifepristone
Mifepristone
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Ensayo de CORCEPT THERAPEUTICS INC en Trastorno depresivo mayor · Trastornos psicoticos.
Más ensayos de: Trastorno depresivo mayor.
- Fase
- Fase 3
- Estado
- Completado
- Participantes
- 104
- Centros
- 19
- Fin del objetivo primario
- nov 2006
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en ago 2005.
Qué mide
Evaluar la seguridad y tolerabilidad de Corlux (mifepristona) para el tratamiento de sintomas psicoticos recurrentes con depresion mayor con caracteristicas psicoticas (PMD) que participaron previamente en el Protocolo C-1073-09 de Corcept Therapeutics
Cómo lo describe el promotor
En el documentoEn inglés, del registroCorlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this study is to allow patients who have already participated in an earlier 8 week study of Corlux versus placebo (an inactive pill) to receive additional courses of treatment with Corlux periodically if a psychotic episode should reappear during a period of one year.
Más ensayos de CORT
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Relacorilant 150 mg | Fase 3 | En marcha, sin reclutar | mar 2025 (real) |
| Relacorilant 150 mg once daily | Fase 2 | Reclutando pacientes | ago 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Nenocorilant 200 mg | Fase 1/2 | Reclutando pacientes | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Dazucorilant 300 mg · DAZALS | Fase 2 | En marcha, sin reclutar | oct 2026 (prevista) |
| Miricorilant | Fase 1 | Reclutando pacientes | oct 2026 (prevista) |
| relacorilant | Fase 2 | En marcha, sin reclutar | dic 2026 (prevista) |
Todos los de CORT, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT00128505), actualizada en feb 2012.